U-Protein Express BV, a wholly owned subsidiary of listed company ImmunoPrecise Antibodies Ltd., has signed a long-term lease agreement with Kadans Science Partner for Accelerator, a new multi-tenant building on Utrecht Science Park.
Accelerator offers accommodation for large Life Sciences companies as well as start-ups and scale-ups that aim to accelerate their development. The design is based on the vision of listed biotechnology companies Genmab and Merus: improving lives of patients by developing innovative therapies for cancer treatment, partly by entering into valuable collaborations. Accelerator endorses this ambition by creating a unique hub within the innovation ecosystem. The building will be developed aiming for high sustainability requirements, BREEAM Excellent, and will have a prominent place at the entrance of Utrecht Science Park.
Dr. Martin Hessing, General Manager of U-Protein Express, stated: “We are delighted to move our continuously expanding service activities towards the new building alongside important stakeholders such as Genmab and Merus. This will enable us the keep in pace with our growing contract research business as Accelerator will give us over 3-4 times current capacity”.
U-Protein Express offers production of recombinant proteins and antibodies for research and preclinical applications. U-Protein Express is part of the ImmunoPrecise Antibodies family, an international, full-service, therapeutic antibody discovery company.
“This transition fits very well into our vision of a global expansion and allows us to offer additional services supporting our philosophy of continuous innovation,” said Dr. Jennifer Bath, President and CEO of ImmunoPrecise.
“We are happy to welcome U-Protein Express to Accelerator. Accelerator is designed to facilitate and connect Life Sciences companies, creating a tight international community within Utrecht Science Park. U-Protein Express is a great addition to the ecosystem and Accelerator will stimulate their growth ambitions,” said Chiel van Dijen, Commercial Director of Kadans Science Partner.
Find out more about Accelerator or contact Johan van Gerven for more information: